drugset / Trial / NCT05712642
A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding : Serum Systemic VEGF levels. Retinal Vascularization.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2020-12-30
- Completion
- 2021-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 0.3125 mg | Intravitreal |
| Subject | Bevacizumab | Monoclonal antibody | 0.625 mg | Intravitreal |